# A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy

> **NCT02365649** · PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 220 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Placebo
- **DRUG:** ABT-494

## Key facts

- **NCT ID:** NCT02365649
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-17
- **Primary completion:** 2016-11-25
- **Final completion:** 2017-08-03
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2023-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02365649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02365649, "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02365649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*